| Literature DB >> 34283079 |
Inja Ilic1, Anton Faron2, Muriel Heimann1, Anna-Laura Potthoff1, Niklas Schäfer3, Christian Bode4, Valeri Borger1, Lars Eichhorn4, Frank A Giordano5, Erdem Güresir1, Andreas H Jacobs6, Yon-Dschun Ko7, Jennifer Landsberg8, Felix Lehmann4, Alexander Radbruch9, Ulrich Herrlinger3, Hartmut Vatter1, Patrick Schuss1, Matthias Schneider1.
Abstract
Neurosurgical resection represents an important therapeutic pillar in patients with brain metastasis (BM). Such extended treatment modalities require preoperative assessment of patients' physical status to estimate individual treatment success. The aim of the present study was to analyze the predictive value of frailty and sarcopenia as assessment tools for physiological integrity in patients with non-small cell lung cancer (NSCLC) who had undergone surgery for BM. Between 2013 and 2018, 141 patients were surgically treated for BM from NSCLC at the authors' institution. The preoperative physical condition was assessed by the temporal muscle thickness (TMT) as a surrogate parameter for sarcopenia and the modified frailty index (mFI). For the ≥65 aged group, median overall survival (mOS) significantly differed between patients classified as 'frail' (mFI ≥ 0.27) and 'least and moderately frail' (mFI < 0.27) (15 months versus 11 months (p = 0.02)). Sarcopenia revealed significant differences in mOS for the <65 aged group (10 versus 18 months for patients with and without sarcopenia (p = 0.036)). The present study confirms a predictive value of preoperative frailty and sarcopenia with respect to OS in patients with NSCLC and surgically treated BM. A combined assessment of mFI and TMT allows the prediction of OS across all age groups.Entities:
Keywords: brain metastases; frailty; non-small cell lung cancer; outcome; overall survival; sarcopenia
Year: 2021 PMID: 34283079 DOI: 10.3390/cancers13133353
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639